市場調查報告書
商品編碼
1001796

癌症肽疫苗的全球市場 - 臨床試驗的考察:2026年

Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026

出版日期: | 出版商: KuicK Research | 英文 275 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

疫苗的開發對人類健康系統產生了不可思議的影響 ,導致多種疾病的死亡率大大降低。含癌症的慢性疾病的盛行率增加,促進新興標靶治療的開發。最近,研究人員在癌症的給藥中,利用產生抗腫瘤反應的疫苗的使用。

本報告提供全球癌症肽疫苗市場相關調查分析,市場趨勢,市場機會,臨床試驗的考察等相關的系統性資訊。

目錄

第1章 癌症肽疫苗的簡介

第2章 肽疫苗的必要性

  • 肽的理由 - 最好
  • 肽疫苗 vs. 傳統疫苗

第3章 肽疫苗的分類

  • 各攝取來源
  • 各長度
  • 各表位

第4章 癌症肽疫苗的作用機制

  • 癌症肽疫苗被活化的免疫細胞
  • 合成肽疫苗的開發次序

第5章 從急性骨髓性白血病的WT1腫瘤性蛋白質攝取的合成肽類似體的臨床試驗有效性分析

  • 研究基本的設計
  • WT1肽的簡介
  • 臨床研究中包含的手法
  • 臨床試驗的結果

第6章 對主要癌症的癌症肽疫苗的廣範圍的作用

  • 大腸癌症
  • 肺癌症
  • 胰臟癌症
  • 胃癌
  • 前列腺癌症
  • 乳癌

第7章 全球癌症肽疫苗市場概要

第8章 全球癌症肽疫苗市場趨勢

  • 最佳化的不可理解的肽
  • 癌症治療用CpG肽為基礎的疫苗
  • 合成長肽的個別化的新抗原疫苗
  • 重組肽疫苗
  • p53肽的脈衝的樹突狀細胞疫苗

第9章 全球癌症肽疫苗的開發平台概要

  • 各國
  • 各企業
  • 各患者市場區隔
  • 各階段

第10章 全球癌症肽疫苗的臨床試驗的考察

  • 研究
  • 前臨床
  • 階段I
  • 階段I/II
  • 階段II
  • 階段III

第11章 LucaVax - 最初上市的癌症肽疫苗

第12章 全球癌症肽疫苗市場動態

  • 推動市場要素
  • 對癌症肽疫苗市場發展的今後課題

第13章 癌症肽疫苗:癌症免疫療法的有力候補

第14章 競爭情形

  • Enzo Life Science (Alexis Biotech)
  • Antigen Express
  • BioLife Science
  • Immatics Biotechnologies
  • Immune Design
  • Imugene
  • Immunomedics
  • ISA Pharmaceuticals
  • Galena Biopharma
  • Generex Biotechnology Corporation
  • Lytix Biopharma
  • Merck (Merck Serono)
  • OncoTherapy Science
  • Oncothyreon
  • Pfizer
  • Phylogica
  • Symphogen (Receptor BioLogix)
  • Sumitomo Dainippon Pharma
  • TapImmune
  • Vaxon Biotech
目錄

“Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026” Report Highlights:

  • Global Peptide Cancer Vaccine Market Trends Insight
  • Global Peptide Cancer Drugs Market Opportunity: >USD 20 Billion
  • Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase
  • Number Of Peptide Vaccines In Pipeline: >90
  • Application of Peptide Cancer Vaccine Against Major Cancer

The developments of vaccines have shown incredible impact on human health system and have resulted in significant decrease in mortality rates from several diseases. Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management. In recent times, researchers have exploited the use of vaccines to generate anti-tumor response in management of cancer.

The rapid approval of Provenge for the management of pancreatic cancer and the robust response in market has surged the development of more targeted vaccines in cancer. In recent times, peptides have emerged as a potential vaccine candidate owing to their small size, simple and cost efficient production and development process. Moreover, peptides are recognized to be highly specific and efficacious, safe and well tolerated. Given their attractive physical and chemical properties, researchers have developed several peptide based vaccines in management of wide range of cancers.

Currently, GV1001 (Riavaxtm, Tertomotide) is the only peptide based vaccine approved for the management of pancreatic cancer in Korea. , GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT). Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells. The vaccine is currently under clinical trials and applications to gain approval in other countries.

Apart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response. Most of the drugs are present in the phase I and II clinical trials which suggests that the market will be flourished with several vaccines targeting different cancers in next 4-5 years. Moreover, in near future the market will see combination of vaccines along with other conventional drugs to improve their efficacy and specificity in targeting the complexity of cancer cells.

Keeping in mind the high adoption rates of the novel therapeutics in North America, it is expected that the region will dominate the global peptide cancer vaccine market for next few years. The high prevalence of cancer and the rising initiatives by government as well as private sectors will also propel the growth of peptide cancer vaccines in this area. In addition to this, Europe and Asia Pacific will also emerge as a potential market wing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector.

As per “Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026” report findings, it is estimated that the global peptide cancer vaccine will follow trajectory growth rates. The market will be favored by the advancement in science and arrival of novel technologies which will further enable the identification of potential targets in developing cancer vaccines. The arrival of peptide based cancer vaccine has caused prompting effects on the overall cancer therapy market and has helped it to make through all the challenges that have been on the way of becoming the most dominant market in the industry.

Table of Contents

1. Introduction to Peptide Cancer Vaccine

2. Need of Peptide Vaccines

  • 2.1 Why Peptides - More Desirable
  • 2.2 Peptide Vaccines V/S Traditional Vaccines

3. Classification of Peptide Vaccines

  • 3.1 On the Basis of Sources Obtained
  • 3.2 On the Basis of Length
  • 3.3 On the Basis of Epitopes

4. Mechanism of Action of Peptide Cancer Vaccines

  • 4.1 Immunological Cells Activated by Peptide Cancer Vaccines
  • 4.2 Procedure of Synthetic Peptide Vaccine Development

5. Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein against Acute Myeloid Leukemia

  • 5.1 Basic Layout of the Study
  • 5.2 Introduction to WT1 Peptide
  • 5.3 Methodologies Involved In the Clinical Study
  • 5.4 Results of the Clinical Trial Study

6. Wide Spectrum Action of Peptide Cancer Vaccines Against Major Cancer

  • 6.1 Colorectal Cancer
  • 6.2 Lung Cancer
  • 6.3 Pancreatic Cancer
  • 6.4 Gastric Cancer
  • 6.5 Prostate Cancer
  • 6.6 Breast Cancer

7. Global Peptide Cancer Vaccine Market Overview

8. Global Peptide Cancer Vaccine Market Trends

  • 8.1 Optimized Cryptic Peptides
  • 8.2 Therapeutic CpG Peptide-Based Cancer Vaccine
  • 8.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides
  • 8.4 Recombinant Peptide Vaccine
  • 8.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines

9. Global Peptide Cancer Vaccine Pipeline Overview

  • 9.1 By Country
  • 9.2 By Company
  • 9.3 By Patient Segment
  • 9.4 By Phase

10. Global Peptide Cancer Vaccine Clinical Trials Insight

  • 10.1 Research
  • 10.2 Preclinical
  • 10.3 Phase-I
  • 10.4 Phase-I/II
  • 10.5 Phase-II
  • 10.6 Phase-III

11. LucaVax - First Commercially available Peptide Cancer Vaccine

12. Global Peptide Cancer Vaccine Market Dynamics

  • 12.1 Market Driving Factors
  • 12.2 Challenges Ahead For Peptide Cancer Vaccine Market Development

13. Peptide Cancer Vaccine: Promising Candidate of Cancer Immunotherapy

14. Competitive Landscape

  • 14.1 Enzo Life Science (Alexis Biotech)
  • 14.2 Antigen Express
  • 14.3 BioLife Science
  • 14.4 Immatics Biotechnologies
  • 14.5 Immune Design
  • 14.6 Imugene
  • 14.7 Immunomedics
  • 14.8 ISA Pharmaceuticals
  • 14.9 Galena Biopharma
  • 14.10 Generex Biotechnology Corporation
  • 14.11 Lytix Biopharma
  • 14.12 Merck (Merck Serono)
  • 14.13 OncoTherapy Science
  • 14.14 Oncothyreon
  • 14.15 Pfizer
  • 14.16 Phylogica
  • 14.17 Symphogen (Receptor BioLogix)
  • 14.18 Sumitomo Dainippon Pharma
  • 14.19 TapImmune
  • 14.20 Vaxon Biotech

List of Figures

  • Figure 1-1: Advantages of Peptide Cancer Vaccines
  • Figure 2-1: Peptides - Amino Acid & Proteins
  • Figure 2-2: Diversification of Vaccines
  • Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines
  • Figure 3-1: Classification of Peptide Vaccine by Source
  • Figure 3-2: Classification on Basis of Length
  • Figure 3-3: On the Basis of Epitopes
  • Figure 4-1: Immunological Cells Activated By Peptide Cancer Vaccines
  • Figure 4-2: Procedure of Synthetic Peptide Cancer Vaccine Development
  • Figure 4-3: Determination of Antigen Components, Its Selection & Construction
  • Figure 4-4: Role of Adjuvants in Peptide Cancer Vaccines
  • Figure 4-5: Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine
  • Figure 5-1: Clinical Trial Study of WT1 Peptide Vaccine for Acute Myeloid Leukemia Patients
  • Figure 5-2: WT1 Peptide as a Marker for Cancer Therapy
  • Figure 5-3: Methodologies Involved In the Clinical Study
  • Figure 6-1: Peptides & Colorectal Cancer
  • Figure 6-2: Peptides & Lung Cancer
  • Figure 6-3: Peptides & Pancreatic Cancer
  • Figure 6-4: Peptides & Gastric Cancer
  • Figure 6-5: Peptides & Prostate Cancer
  • Figure 6-6: Peptides & Breast Cancer
  • Figure 7-1: Global - Peptide Therapeutic Market Size (US$ Billion), 2018 - 2026
  • Figure 7-2: Global - Total Peptide Therapeutic Market Size vs. Oncological Peptide Therapeutic Market Size (US$ Billion), 20120
  • Figure 7-3: Global - Oncological Peptide Therapeutics Market Share in Total Peptide market (%), 2020
  • Figure 7-4: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2018 - 2026
  • Figure 7-5: Peptide Oncology Market - Regional Market Share (%), 2019
  • Figure 8-1: Optimized Cryptic Peptides
  • Figure 8-2: Therapeutic CpG Peptide-Based Cancer Vaccine
  • Figure 8-3: Personalized Neoantigen Vaccination with Synthetic Long Peptides
  • Figure 8-4: Recombinant Peptide Vaccine
  • Figure 8-5: p53 Peptide-Pulsed Dendritic Cells Cancer Vaccine
  • Figure 9-1: Global - Peptide Cancer Vaccine in Clinical Pipeline by Country, 2021 till 2026
  • Figure 9-2: Global - Peptide Cancer Vaccine in Clinical Pipeline by Company, 2021 till 2026
  • Figure 9-3: Global - Peptide Cancer Vaccine in Clinical Pipeline by Patient Segment, 2021 till 2026
  • Figure 9-4: Global - Peptide Cancer Vaccine in Clinical Pipeline by Phase, 2021 till 2026
  • Figure 12-1: Market Drivers of Peptide Cancer Vaccines
  • Figure 12-2: Peptide Cancer Vaccine: An Active Immunotherapy
  • Figure 12-3: Peptide Cancer Vaccine: A Personalized, Targeted Therapy
  • Figure 12-4: Peptide Cancer Vaccine: Highly Efficient, High Immunogenic Response Generating
  • Figure 12-5: Peptide Cancer Vaccine: Multiple Tumors Targeting Ability
  • Figure 12-6: Peptide Cancer Vaccine: A Viable Solution to Immunotolerance
  • Figure 12-7: Peptide Cancer Vaccine: Improves the Quality Of Life & is Cost Effective
  • Figure 12-8: Challenges of Peptide Cancer Vaccine: The Parameters Related To the Clinical Trials
  • Figure 12-9: Single Antigen Based Peptide Vaccine: Highly Prone To Failure
  • Figure 12-10: Lack of Standardized Parameters for Assessing the Result of Clinical Trials
  • Figure 12-11: Variable Therapeutic Window for Different Patients
  • Figure 12-12: Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape
  • Figure 14-1: Enzo Life Science Pipeline
  • Figure 14-2: Immatics Biotechnologies Pipeline
  • Figure 14-3: Immune Design Pipeline
  • Figure 14-4: Imugene Pipeline
  • Figure 14-5: ISA Pharmaceuticals Pipeline
  • Figure 14-6: Galena Biopharma Pipeline
  • Figure 14-7: Generex Biotechnology Pipeline
  • Figure 14-8: Lytix Biopharma Pipeline
  • Figure 14-9: Merck Clinical Pipeline
  • Figure 14-10: Onco Therapy Science Pipeline
  • Figure 14-11: Oncothyreon Pipeline
  • Figure 14-12: Sumitomo Dainippon Pharma Pipeline
  • Figure 14-13: Tapimmune Pipeline
  • Figure 14-14: Vaxon Biotech Pipeline